Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Mitsubishi Tanabe, Pfizer to Copromote 5-in-1 Vaccine Gobik
January 24, 2024
- Prefilled Syringe Versions of Hizentra Approved in Japan: CSL
January 23, 2024
- Nippon Shinyaku Snags EU Orphan Tag for EGPA Drug
January 23, 2024
- Moderna Japan Files 0.5 mL Vial Formulation for Spikevax
January 22, 2024
- Employee Sues Alexion for Sidelining in Reprisal against Whistleblowing
January 19, 2024
- Daiichi, Mitsubishi Curb MR Vaccine Shipments in Response to Takeda’s Recall
January 19, 2024
- LEO Pharma Poised to Build Presence in Japan as Dermatology Leader: CEO
January 19, 2024
- Sawai Exits US Biz to Cope with GMP and Supply Issues in Japan
January 18, 2024
- Takeda’s Hyqvia Earns US Nod for CIDP Maintenance Therapy
January 18, 2024
- US Patent Office Nixes Seagen Patent in ADC Row: Daiichi Sankyo
January 18, 2024
- Ono Deplores Regulator’s Decision on Opdivo Spillover Re-Pricing
January 18, 2024
- Parmodia Tops November GP Rep Promotion List, Dayvigo HP Champion for 4th Month
January 18, 2024
- Resuming Production at Quake-Hit Plant Will Take Some Time: Santen
January 17, 2024
- Daiichi Sankyo to Discontinue Sales of Herceptin Biosimilar in November
January 17, 2024
- Taisho Set for Delisting as Early as April after Tender Offer Completed
January 17, 2024
- Taisho’s Nanozora Autoinjector Goes on Sale in Japan
January 17, 2024
- Amgen Files TED Drug Tepezza in Japan
January 17, 2024
- Novo Nordisk Begins Normal Shipments for Ozempic in Japan
January 17, 2024
- Pfizer’s Ibrance Bags Label Update for Tamoxifen Combo in Breast Cancer
January 16, 2024
- Leqembi’s Anticipated EU Approval Delayed into April-June 2024: Eisai
January 15, 2024
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…